📡 AI Distill ── 2026-06-25

## Key Issues in Applying Generative AI to Pharmaceutical and Materials Review **Benefits** Both PMDA and FDA acknowledge the potential for AI to accelerate review, summarization, and data extraction. Large-scale clinical documents (CSRs, CTDs), publications, manufacturing records, and promotional materials can be screened, cross-checked for consistency, and standardized in terminology at speed, reducing reviewer cognitive load. The FDA introduced an internal LLM called "Elsa" in 2025. **Risks** The central problems are **hallucination** (fabricated citations and data) and lack of reproducibility. Other concerns include training-data bias, leakage of sensitive clinical and personal information (GDPR, Act on the Protection of Personal Information), prompt injection, and the absence of accountability due to black-box opacity. In materials review, delegating judgment on violations of the Pharmaceutical and Medical Device Act (PMDA) — such as exaggerated advertising (Article 66) or off-label promotion — entirely to AI creates ambiguity around legal liability for erroneous determinations. **Implementation Considerations** - **Human-in-the-loop is mandatory**; AI assists and drafts only. Final decisions rest with qualified personnel (regulatory affairs, MR-certified, ethics committee members). - **Context-of-use validation** and audit-trail retention aligned with GAMP 5 and the FDA "AI/ML Trustworthiness Framework" (2025 draft). - Use retrieval-augmented generation (RAG) to ensure verifiability; generated outputs must always be traced back to primary sources. - Closed environments and data governance to prevent information leakage. - Data integrity ensured by ALCOA+ principles. The essential line to draw: AI is an efficiency tool, not a decision-maker. A regulatory-compliant validation framework is the prerequisite. **Key References** - FDA, "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products" (Draft Guidance, 2025) - ICH M11/E6(R3) Good Clinical Practice (2023–) - ISPE, "GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems" (2nd ed., 2022) - EMA, "Reflection Paper on the Use of AI in the Medicinal Product Lifecycle" (2024) - MHLW, "Pharmaceutical Advertising Regulation" and PMDA Article 66 (prohibition of exaggerated advertising)

## Applying Generative AI (LLMs) to Pharmaceutical and Materials Review ### Key Benefits - **Efficiency**: Up to 60–70% reduction in package insert and CTD review time (McKinsey estimate, 2023) - **Consistency**: Uniform application of review standards, reduced human error - **Regulatory tracking**: Automated monitoring of ICH, FDA, and PMDA guideline updates ### Key Risks - **Hallucination**: Fabricated literature citations and dosage figures — fatal when linked to clinical judgment - **Bias propagation**: Skew in training data seeping into review decisions - **Data leakage**: Compliance risk of transmitting unpublished trial data via API - **Accountability gap**: FDA 21 CFR Part 11 and the EU AI Act (2024) require audit trails for AI-driven decisions ### Implementation Considerations 1. **Human-in-the-loop is mandatory**: Regulatory specialists must underwrite final decisions 2. **On-premises or private cloud**: Confidential trial data must be processed in closed networks 3. **Validation**: Performance verification aligned with FDA "AI/ML-Based SaMD Action Plan" (2021) 4. **Change management**: Re-validation procedures documented at every model update --- **Key References** - FDA. *Artificial Intelligence and Machine Learning in Software as a Medical Device* (2021) - European Parliament. *EU Artificial Intelligence Act* (2024, Regulation 2024/1689) - ICH. *E9(R1) Statistical Principles for Clinical Trials: Addendum on Estimands* (2019) - Moor M et al. "Foundation models for generalist medical artificial intelligence." *Nature* 616, 259–265 (2023) - McKinsey Global Institute. *The Economic Potential of Generative AI* (2023)

## PMDA Articles 66–68 — Prohibition of Exaggerated Advertising **Regulatory Purpose** Pharmaceuticals involve severe information asymmetry; erroneous advertising can directly cause harm and improper use. The Act on Pharmaceutical and Medical Devices (renamed from the Pharmaceutical Affairs Act in the 2014 revision) therefore regulates advertising across three articles, with the objectives of protecting consumers and ensuring appropriate use. - **Article 66 (False or Exaggerated Advertising)**: Prohibits describing or disseminating content that is false or exaggerated regarding efficacy, effect, performance, or safety — whether explicit or implied. Guarantees by physicians and references to abortion or obscene material are also prohibited. The prohibition applies to **anyone** (not limited to marketing authorization holders), with criminal penalties. - **Article 67**: Restricts advertising for pharmaceuticals designated for specific serious diseases (e.g., cancer) from reaching non-healthcare professionals (by cabinet order). - **Article 68 (Prohibition of Advertising Unapproved Products)**: Absolutely prohibits advertising of names, indications, or other details of products before approval or certification. Known as the "pre-approval advertising" prohibition; enforcement has increased in recent years for unapproved online sales and implied health food claims. **Operational Rules** Detailed judgments are governed by the MHLW "Standards for Appropriate Advertising of Pharmaceuticals" (1980 notification, fully revised 2017), which specifies prohibitions on superlative claims of efficacy, safety guarantees, disparagement of competitors, and endorsements by healthcare professionals. Beyond administrative guidance and improvement orders, a **surcharge system** introduced in the 2021 revision (Article 75-5-2; 4.5% of revenues from false or exaggerated advertising) strengthens deterrence. Enforcement is handled by prefectural pharmaceutical affairs offices and an internet patrol program. **Key References** - PMDA Articles 66–68 and Article 75-5-2 (surcharge) - MHLW "Standards for Appropriate Advertising of Pharmaceuticals" (Yakusei-hatsu 0929 No. 4, September 29, 2017) - MHLW Pharmaceutical Safety and Environmental Health Bureau, Compliance and Narcotics Division, "Pharmaceutical Advertising Q&A" - Yakuji-ho Kenkyu-kai (ed.), *Commentary on the Act on Pharmaceutical and Medical Devices* (Yakuji Nippo) - MHLW "Internet Sales and Advertising Surveillance (Cyber Patrol) Program" report

## PMDA Articles 66–68: Prohibition of Exaggerated Advertising **Regulatory Purpose** To prevent consumers from being misled about the efficacy and effects of pharmaceuticals and medical devices in ways that lead to improper use or delayed medical consultation. The legislative purpose is to prevent public health harm and ensure appropriate use. **Scope of Each Article** | Article | Prohibited Conduct | |---------|-------------------| | Art. 66 | Advertising, describing, or disseminating false or exaggerated content (including misrepresentation of efficacy, effect, or performance) | | Art. 67 | Restrictions on general public advertising for products targeting specific diseases (cancer, leukemia, AIDS, etc.) | | Art. 68 | Prohibition of advertising unapproved or uncertified products | **Key Operational Points** - **Article 66** applies to "anyone" — marketing authorization holders, advertising agencies, and social media posters alike. The 2021 revision introduced a surcharge system (4.5% of sales revenue from violations, effective August 2021). - The MHLW "Standards for Appropriate Advertising of Pharmaceuticals" (established 1980, revised 2017) sets out operational rules, specifically prohibiting superlative expressions ("best," "strongest"), implied efficacy through testimonials, and selective citation of academic papers. - Article 68 violations (advertising unapproved products) carry up to two years imprisonment or a fine of up to 2 million yen. Enforcement against social media and video streaming has intensified since 2023, with PMDA and prefectural authorities jointly investigating influencer cases. --- **Key References** - MHLW, "Standards for Appropriate Advertising of Pharmaceuticals" (Yakusei-hatsu 0929 No. 4, 2017) - PMDA Articles 66–68 with article-by-article commentary (Jiho, 2021 ed.) - Japan Pharmaceutical Law Society, *Practice and Theory of Pharmaceutical Regulation* (4th ed., 2022) - PMDA "Guidance on the Surcharge System" (published August 2021) - Kikuchi Koji, "Practical Response to Exaggerated Advertising Regulation under the Revised PMDA," *Yakuji* Vol. 74 No. 3 (2022)

## Guidelines on Sales Information Provision Activities (Hantei-G): Regulatory Purpose and Impact on MR Activities **Official Title and Background** "Guidelines on Sales Information Provision Activities for Prescription Pharmaceuticals" (MHLW Pharmaceutical Safety and Environmental Health Bureau Director notification, issued September 2018, effective April 2019). The background includes clinical research data manipulation and exaggerated advertising controversies involving pharmaceutical companies in 2013–2014 — such as the Diovan (valsartan) case — and the guidelines were established as a quasi-voluntary regulatory framework complementing PMDA Articles 66–68 (prohibition of false/exaggerated advertising and unapproved drug advertising). **Regulatory Purpose** To eliminate implied off-label use and biased presentation of efficacy and safety data, and to ensure scientifically grounded, objective information provision. The scope covers all "sales information provision activities" not classified as advertising — including verbal explanations, emails, briefings, and e-promotion — and mandates presentation of evidence alongside mandatory disclosure of unfavorable information (adverse reactions, etc.). **Impact on MR Activities** 1. **Documentation and monitoring systems**: Companies are required to establish a supervisory division for sales information provision activities, conduct pre-approval materials review, and retain activity records. MRs' verbal explanations became subject to control. 2. **Materials control**: Use of proprietary materials implying comparative advantage or off-label information is restricted; alignment with approved indications and peer-reviewed literature is now the standard. 3. **Speaker programs and MSL roles**: KOL speaker programs saw clearer separation from Medical Science Liaison (MSL) functions, and the boundary between MR promotion and information provision was formalized. 4. Violations carry both guideline-level guidance and the risk of PMDA violations. As a result, MR activity shifted from "aggressive promotion" to "information provision that is documentable and withstands scrutiny." **Key References** - MHLW, "Guidelines on Sales Information Provision Activities for Prescription Pharmaceuticals" (Yakusei-hatsu 0925 No. 1, 2018) - MHLW, "Q&A on the Guidelines" (2019) - PMDA Articles 66 and 68 (prohibition of exaggerated and unapproved drug advertising) - Japan Pharmaceutical Manufacturers Association (JPMA) Code of Practice - Report of the Review Committee on Hypertension Research Related to the Diovan Case (2014)

## Regulatory Purpose of Hantei-G and Its Impact on MR Activities **Regulatory Purpose** MHLW notification of September 2018, effective April 2019. Prompted by the recognition that off-label or unapproved information provision that steered prescriptions posed a threat to patient safety, the guidelines established two pillars: "prohibition of proactive provision of off-label information" and "appropriate provision of information based on scientific evidence." The background includes the 2014 Novartis Diovan case and related instances of improper pharmaceutical company data use. **Key Impacts on MR Activities** - Spontaneous explanation of off-label indications or dosages is in principle prohibited - Internal pre-approval review of explanatory materials for consistency with approved indications is now mandatory - Even passive "reactive" information provision in response to physician inquiries requires written documentation - Violations are subject to improvement guidance and possible business suspension orders (under the PMDA) MR discretion was substantially curtailed, driving industry-wide reinforcement of compliance education and materials management. --- **Key References** - MHLW, "Guidelines on Sales Information Provision Activities for Prescription Pharmaceuticals" (Yakusei-hatsu 0925 No. 1, September 25, 2018) - JPMA, "Rules and Standards Related to the MR Certification System" (2019 revised edition) - Yakuji Nippo, "Survey of Pharmaceutical Company Responses after Hantei-G Implementation" (2020) - PMDA Article 68 (prohibition of exaggerated advertising) - National Institute of Health Sciences, "International Comparison of Pharmaceutical Promotion Regulation" (2020)

## From the Nuremberg Code to the Declaration of Helsinki: Where We Stand The Nuremberg Code (1947) emerged from the Doctors' Trial following Nazi human experimentation. It placed "the voluntary consent of the human subject is absolutely essential" as its first principle, though it lacked binding force directed at the medical profession. The World Medical Association (WMA) systematized this into a code of professional self-regulation in the 1964 Declaration of Helsinki, built on three pillars: (1) independent review of research protocols (the future ethics committee/IRB), (2) the primacy of subject welfare over scientific and social benefit, and (3) documented informed consent. The 1975 Tokyo revision explicitly mandated independent committee review; the 2000 Edinburgh revision addressed contested placebo use and post-trial access; the 2013 Fortaleza revision strengthened victim compensation, trial registration, and mandatory result publication; and the 2024 Helsinki revision advanced protection of vulnerable populations and a redefinition of informed consent. The current state of the field reflects the translation of abstract declarations into legally and operationally binding norms in individual countries — via the Belmont Report (1979: respect for persons, beneficence, justice), CIOMS Guidelines, and ICH-GCP (E6). The center of gravity has shifted from consent-centrism to a multi-layered governance model encompassing independent review, conflict-of-interest management, transparency (trial registration and result disclosure), and protection of vulnerable populations. **Key References** - WMA, *Declaration of Helsinki* (1964, 2013 Fortaleza revision, 2024 revision) - *The Nuremberg Code* (1947), Trials of War Criminals - National Commission, *The Belmont Report* (1979) - CIOMS, *International Ethical Guidelines for Health-related Research Involving Humans* (2016) - ICH, *Guideline for Good Clinical Practice E6(R2/R3)*

## The State of Medical Research Ethics: Nuremberg → Helsinki **1947 Nuremberg Code**: Born from the reflection on Nazi human experimentation; "voluntary consent" codified as an absolute condition. Its ten principles formed the foundation of research ethics. **1964 Declaration of Helsinki (WMA)**: Integrated the Code into physician professional ethics. Distinguished between therapeutic and non-therapeutic research; added the "priority of patient welfare." **Accumulated Key Revisions**: The 1975 Tokyo revision made IRB review mandatory; the 2000 Edinburgh revision tightened restrictions on placebo use; the **2013 Fortaleza revision** (current version) explicitly addressed (1) big data and biobank applications, (2) guaranteed post-trial access to beneficial treatment, and (3) strengthened protection of vulnerable populations. **Current State**: Informed consent, independent ethical review, risk minimization, and transparent publication of results are now the four-element international standard. ICH-GCP (E6) translates these into regulation, with direct implications for FDA and EMA approval review. --- **Key References** - Nuremberg Military Tribunals. *Trials of War Criminals*, Vol. 2, 1949 (full text of the Nuremberg Code) - World Medical Association. *Declaration of Helsinki*, 2013 revision. JAMA 310(20):2191–2194 - Beauchamp TL, Childress JF. *Principles of Biomedical Ethics*, 8th ed. Oxford UP, 2019 - ICH Harmonised Guideline. *Good Clinical Practice E6(R2)*, 2016 - Carlson RV et al. "The revision of the Declaration of Helsinki." *Lancet* 359(9305):433–434, 2002

# Pharmaceutical Company Ethics — The Tension Between Profit and Medicine Pharmaceutical companies carry a simultaneous obligation to maximize profit for shareholders and a responsibility toward the public good of patient health. This structural tension sits at the center of research ethics and industry ethics. **Information Asymmetry and Conflicts of Interest**. Sponsor funding of clinical trials produces systematic bias in results reporting (publication bias, ghostwriting). Merck's withdrawal of Vioxx (2004) and a major pharmaceutical company's pediatric data issues with Paxil demonstrated that selective disclosure of harm data can cause real-world injury. In response, ICMJE mandatory trial pre-registration (ClinicalTrials.gov, from 2005), the AllTrials movement, and conflict-of-interest disclosure requirements (US Physician Payments Sunshine Act, 2010) have been institutionalized. **Access and Pricing**. High drug prices for rare diseases and new therapies, and the gap in pharmaceutical access in low- and middle-income countries, are debated as a conflict between patent rights (TRIPS) and human rights (the right to health). The Access to Medicine Index evaluates companies on this axis. The mainstream view has converged on the position that self-regulation alone is insufficient, and that transparency, independent regulation (FDA/EMA), and third-party auditing as external controls are essential. IFPMA Code of Practice and stakeholder capitalism discourse also ultimately treat verifiable disclosure as the basis of trust. **Key References** - Angell M. *The Truth About the Drug Companies* (2004) - Goldacre B. *Bad Pharma* (2012) - Lo B. & Field MJ (eds.), IOM *Conflict of Interest in Medical Research* (2009) - WHO/WMA *Declaration of Helsinki* (1964, 2013 revision) - Access to Medicine Foundation, *Access to Medicine Index* (biennial)

## Pharmaceutical Company Ethics: The Tension Between Profit and Medicine **Where the Structural Tension Lies** Pharmaceutical companies simultaneously bear fiduciary duties to shareholders and medical responsibilities to patients. This dual obligation became visible with regulatory tightening following the 1962 Kefauver-Harris Amendments (prompted by the thalidomide disaster). **Key Issues** - **Pricing and public health**: Sovaldi (hepatitis C drug, 2013) at $84,000 per course crystallized internationally the "curable but unaffordable" problem - **Evidence manipulation**: As Goldacre (2012) demonstrated, industry-sponsored trials show roughly twice the positive-result publication bias of independent trials - **Off-label promotion**: In the US in the 2000s, Pfizer and other major pharmaceutical companies paid combined settlements of tens of billions of dollars, exposing the limits of industry self-regulation (PhRMA Code) - **Rare diseases vs. blockbusters**: The Orphan Drug Act (1983) tax incentives spurred rare-disease development but also created structural incentives toward high pricing **The Current Regulatory Equilibrium** ICH-E6 GCP revisions (2016/2022), the PRAXIS framework, and EU pharmaceutical regulation (EMA) have standardized transparency obligations and COI disclosure. "Patient-centricity" is now a regulatory requirement, not a voluntary virtue. --- **Key References** - Goldacre B. *Bad Pharma*. 2012, Fourth Estate - Angell M. *The Truth About the Drug Companies*. 2004, Random House - Lexchin J. "Relationship between Pharmaceutical Company User Fees and Drug Approvals in Canada and Australia." *Annals of Internal Medicine*, 2006 - PhRMA Code on Interactions with Healthcare Professionals. 2022 revision - ICH E6(R3) Good Clinical Practice Guideline. 2023

Pharmaceutical CEO decision-making operates within ICH E6(R2/R3) and GxP regulation as given constraints, optimizing simultaneously for patient safety and corporate survival. Two elements are central. **ERM (Enterprise Risk Management)**: Using COSO-ERM (first edition 2004, revised 2017) and ISO 31000 as frameworks, risk is treated not as a "threat to avoid" but as "uncertainty integral to strategy." Pharma-specific risks — clinical trial failures, pharmacovigilance safety signals, supply chain disruptions, patent cliffs — are articulated as risk appetite and allocated at the portfolio level. Decisions are based on risk-adjusted net present value (rNPV), and the discipline of exit decisions (kill decisions) affects company value more than success rates alone. **Compliance Management**: Against the backdrop of the 2003 US OIG Guidance, Corporate Integrity Agreements (CIAs), the Sunshine Act (2010), and Japan's Transparency Guidelines (2011, JPMA), controls are applied to promotion, conflicts of interest, and bribery (FCPA). The key shift is from "rule compliance" to internalization of a corporate culture and ethics anchored in Tone at the Top. The three-lines model — which keeps the second line (compliance) and third line (internal audit) independent — is used to ensure the CEO guarantees a verifiable control environment. In short, the modern essential is to convert regulation into a source of competitive advantage, and to build an organization where bad news travels upward through psychological safety. **Key References** - COSO, *Enterprise Risk Management—Integrating with Strategy and Performance* (2017) - ISO 31000:2018, *Risk management—Guidelines* - US OIG, *Compliance Program Guidance for Pharmaceutical Manufacturers* (2003) - ICH E6(R3), *Good Clinical Practice* (2023) - JPMA, *Guidelines on Transparency of Relationships between Corporate Activities and Medical Institutions* (2011)

## Pharmaceutical CEO Decision-Making: ERM and Compliance Management Essentials **Structural Features** Modern pharmaceutical CEOs simultaneously manage three layers: "scientific uncertainty," "regulatory risk," and "market risk." Since the Sarbanes-Oxley Act of 2002 (SOX), internal control reporting to the board became mandatory, and ERM shifted to integrated risk management aligned with the COSO framework (2017 revision). **The Core of Decision-Making** - **Explicit Risk Appetite**: FDA/EMA pre-consultation (Pre-IND meeting) results quantitatively reported to the Board - **Three-lines defense model**: Independence of business units → compliance department → internal audit - **Post-market surveillance**: Following a major pharmaceutical company's China bribery case (fine of approximately ¥49 billion, 2013) and Abbott's off-label sales (approximately ¥170 billion settlement, 2012), personal CEO accountability for ethical sales practices was clarified **Recent Trends** ESG-integrated ERM has become mainstream, and since 2021 the SEC has required enhanced disclosure of climate and social risks. Johnson & Johnson and Novartis elevated the Chief Ethics & Compliance Officer (CECO) to the C-suite with a direct reporting line to the CEO. --- **Key References** - COSO (2017). *Enterprise Risk Management — Integrating with Strategy and Performance* - FDA (2019). *Compliance Program Guidance Manual* - Kesselheim, A.S. et al. (2011). "False claims act prosecutions." *JAMA*, 305(6), 602–611 - Leisinger, K.M. (2012). *Business Ethics and Corporate Sustainability*. Edward Elgar - DiMasi, J.A. et al. (2016). "Innovation in the pharmaceutical industry." *Journal of Health Economics*, 47, 20–33

Corporate governance in life-science industries (pharmaceuticals, healthcare, food) is discussed on the premise of three structural features that differ from general industries. **Information Asymmetry**: The efficacy and safety of pharmaceuticals cannot be evaluated without specialist knowledge, and there are severe information gaps among patients, physicians, regulators, and companies. As George Akerlof's lemons market theory (1970) demonstrates, asymmetry disables market self-correction — which is why institutional design centering on third-party verification and compulsory disclosure (trial registration, package inserts, PMS) to bridge these gaps is the core of FDA (1962 Kefauver-Harris Amendments) and ICH-GCP (1996) regulation. **The Slowness of Trust Accumulation**: Establishing safety requires long-term clinical trials and post-marketing surveillance (pharmacovigilance), and trust can only be built up over years. The "dual wheel" of "competence and ethics" — as Edelman Trust Barometer data illustrate — is cultivated only through a consistent track record of regulatory compliance and scientific integrity. **The Speed of Trust Loss**: By contrast, accidents and cover-ups destroy trust instantaneously. Thalidomide (around 1960), the Vioxx recall (2004), and Japan's Diovan research fraud (2013) are examples of single incidents damaging corporate value and the social license of an entire industry. Because of this asymmetric collapse speed, modern corporate governance theory regards patient-centricity, the precautionary principle, and transparency — beyond shareholder value maximization — as conditions of the "license to operate." The mainstream understanding treats information disclosure and internal control (COSO) not as costs but as investments in preserving trust capital. **Key References** - Akerlof, G. "The Market for Lemons" (*QJE*, 1970) - Avorn, J. *Powerful Medicines* (2004) - Carpenter, D. *Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA* (2010) - ICH *Good Clinical Practice (E6)* Guideline (1996, R2 2016) - OECD *Principles of Corporate Governance* (2023 revision)

## Distinctive Features of Life-Science Industries: Information Asymmetry and the Accumulation and Collapse of Trust **Information asymmetry** is a structural premise of the pharmaceutical and medical device industry. As Freeman's (1984) stakeholder theory notes, patients, physicians, and regulators cannot have symmetric information with manufacturers. To correct for this, the FDA (1962 Kefauver-Harris Amendments) and EMA (established 1995) institutionalized third-party review of efficacy and safety — though selective disclosure of clinical trial data (publication bias) remains a concern today. **Trust accumulation** is long-term and cumulative, functioning as reputation capital (Fombrun 1996) rather than brand equity. Patients' medication adherence and physicians' prescribing choices depend on decades of accumulated safety records and scholarly evidence. **Trust loss is asymmetrically fast**. In the Johnson & Johnson Tylenol incident (1982), market share collapsed overnight; in Merck's Vioxx withdrawal (2004), allegations of concealed cardiovascular risk erased over $30 billion in market capitalization within weeks. As Weick's (1993) theory of organizational collapse shows, trust loss proceeds nonlinearly and irreversibly. Current ESG and corporate governance doctrine (OECD Principles, 2023 revision) identifies this asymmetry as the core challenge of risk management. --- **Key References** - Freeman, R.E. (1984). *Strategic Management: A Stakeholder Approach*. Pitman. - Fombrun, C.J. (1996). *Reputation: Realizing Value from the Corporate Image*. Harvard Business School Press. - Weick, K.E. (1993). The collapse of sensemaking in organizations. *Administrative Science Quarterly*, 38(4), 628–652. - OECD (2023). *G20/OECD Principles of Corporate Governance*. OECD Publishing. - US Congress (1962). Kefauver-Harris Drug Amendments. Public Law 87-781.

# Freud, Jung, and Adler on Self-Understanding **Freud (Sigmund Freud, 1856–1939)** founded psychoanalysis and conceived self-understanding as "making the unconscious conscious." He divided the mind into the conscious, preconscious, and unconscious, later presenting the structural model of id, ego, and superego (1923, *The Ego and the Id*). Bringing repressed infantile drives and conflicts to language through free association and dream analysis became the core of both treatment and self-insight. **Jung (Carl Jung, 1875–1961)** established analytical psychology after the split (around 1913). In addition to the personal unconscious, he posited a "collective unconscious" containing archetypes shared by all humanity, defining self-understanding as the process of **individuation** — integrating conscious and unconscious. His typology of introversion/extraversion (1921) is the theoretical source of the MBTI. **Adler (Alfred Adler, 1870–1937)** proposed Individual Psychology. Rather than sexual drives, he centered on **inferiority feelings and their compensation** and the striving for superiority, holding that the human being as an indivisible whole moves toward purposes (teleology). He emphasized "lifestyle" and "social interest" (Gemeinschaftsgefühl), regarding self-understanding as the reconstruction of goals in a social context. **Influence on the Present**: Freud's concept of the unconscious became a foundation for clinical psychology broadly, with his theory of defense mechanisms inherited by stress research. Jung's typology spread into personality psychology and career theory; his archetypes into narrative theory and cultural studies. Adler's teleology and cognitive reframing connect directly to cognitive behavioral therapy (CBT), positive psychology, and the recent self-help phenomenon (*The Courage to Be Disliked*). All three face empirical criticism, but left the dynamic perspective and human vision at the heart of psychotherapy. **Key References** - Freud, S. (1923) *Das Ich und das Es* - Jung, C.G. (1921) *Psychologische Typen* - Adler, A. (1927) *Menschenkenntnis* - Ellenberger, H.F. (1970) *The Discovery of the Unconscious* - Taro Tobira et al., *Introduction to Clinical Psychology*

## Freud, Jung, and Adler: Self-Understanding Frameworks and Their Modern Influence **Freud** (1856–1939) presented the three-layer structure of unconscious, preconscious, and conscious, along with the id/ego/superego model. He held that repressed drives distort self-perception, and made free association and dream analysis the means of self-understanding. This became the foundation for subsequent psychoanalytic therapies (object relations theory, self-psychology). **Jung** (1875–1961) introduced the collective unconscious and archetype concepts, positioning the process of individuation as the core of self-realization. He became the theoretical source of the MBTI, and his influence extends to modern narrative therapy and transpersonal psychology. **Adler** (1870–1937) proposed a teleological self-understanding centered on the compensation of inferiority feelings and social interest (Gemeinschaftsgefühl). His affinity with cognitive behavioral therapy (CBT) and positive psychology's "focus on strengths" is high; his reappraisal accelerated with the translation by Ichiro Kishimi of *The Courage to Be Disliked* (2013). Common to all three is the view that making unconscious motivations visible is the starting point for self-transformation — structurally inherited by modern introspective tools (ACT, mindfulness). --- **Key References** - Freud, S. (1923). *The Ego and the Id*. Hogarth Press. - Jung, C. G. (1959). *The Archetypes and the Collective Unconscious* (CW 9i). Princeton UP. - Adler, A. (1927). *Understanding Human Nature*. Greenberg. - Ellenberger, H. F. (1970). *The Discovery of the Unconscious*. Basic Books. - Ansbacher, H. L., & Ansbacher, R. R. (Eds.) (1956). *The Individual Psychology of Alfred Adler*. Basic Books.

The Dunning-Kruger effect refers to findings published in 1999 by Justin Kruger and David Dunning in the *Journal of Personality and Social Psychology*, showing that people with lower ability tend to overestimate their own performance. The core cause is the "metacognitive blind spot" — specifically, the "dual burden": the skills needed to get the right answer are the same skills needed to recognize one's mistakes. When competence is lacking, one not only fails at the task but cannot perceive the failure itself. Current mainstream understanding is somewhat cautious. First, high performers tend to underestimate themselves, so the effect is not symmetric across the full distribution. Second, Nuhfer et al. (2016–2017) and statistical critics have pointed out that some of the original data can be explained by regression to the mean and measurement error, and that the same figure emerges from noise data. In other words, the debate is about effect size, not the existence of the effect itself. However, the core finding — that metacognitive accuracy correlates with competence — is broadly supported across multiple replications. Dunning himself has in recent years reformulated the issue as a problem of asymmetric confidence: "ignorance comes with certainty." **Key References** - Kruger, J. & Dunning, D. (1999). *J. Pers. Soc. Psychol.*, 77(6), 1121–1134. - Dunning, D. (2011). "The Dunning-Kruger Effect." *Advances in Experimental Social Psychology*, 44. - Nuhfer, E. et al. (2016/2017). *Numeracy*, 9(1) & 10(1). - Ehrlinger, J., Johnson, K., Banner, M., Dunning, D., Kruger, J. (2008). *Organizational Behavior and Human Decision Processes*, 105(1). (approx. 580 characters)

## The Dunning-Kruger Effect and Metacognitive Blind Spots In 1999, David Dunning and Justin Kruger (Cornell University) demonstrated experimentally that those with lower ability tend to have inflated self-assessments (*Journal of Personality and Social Psychology*). The root cause is the **dual burden**: skill deficits not only degrade actual performance but also impair the very metacognitive ability needed to recognize those deficits. From the 2010s onward, however, re-analyses accumulated. Gignac & Zajenkowski (2020) and others argued that "statistical artifacts (regression to the mean)" exaggerate the effect size. Nuhfer et al. (2017) reported that the "U-shaped" pattern disappears in large-scale data. The current mainstream holds a moderate position: "the effect is real but small to moderate, and domain-specific." The metacognitive blind spot derives from Flavell's (1979) framework, emphasizing that the accuracy of self-monitoring depends on experience and feedback density. --- **Key References** - Kruger & Dunning (1999). *J. Personality & Social Psychology*, 77(6). - Nuhfer et al. (2017). *Numeracy*, 10(1). - Gignac & Zajenkowski (2020). *Intelligence*, 80. - Flavell (1979). *American Psychologist*, 34(10). - Ehrlinger et al. (2008). *Organizational Behavior & Human Decision Processes*, 105(1).

## Critical Reassessment of the Self-Esteem Construct The turning point was a meta-analysis by Roy Baumeister et al. published in 2003 in *Psychological Science in the Public Interest*. They concluded that evidence for high self-esteem causally improving academic performance, occupational success, or interpersonal relationships was weak, and that many correlations ran in the opposite direction (success raises self-esteem) or reflected third variables. The assumption underlying the 1980s–90s California self-esteem movement (led by John Vasconcellos) — that raising self-esteem would reduce social problems — was not supported. Moreover, inflated self-esteem was found to be associated with aggression and narcissism (Bushman & Baumeister 1998). In response to this critique, focus shifted to **competence beliefs and self-relationship rather than evaluation**. Bandura's **self-efficacy** (1977, 1997) — beliefs about one's capacity to execute a specific task — shows high behavioral predictive validity and is amenable to intervention. Where self-esteem is a global emotional appraisal ("am I a person of worth?"), efficacy is domain-specific and directly linked to behavior. Neff's **self-compassion** (2003) — comprising kindness to oneself, common humanity, and mindfulness — avoids the fragility of self-esteem (conditional, defensively inflated) by not anchoring self-evaluation to comparison with others. Research shows self-compassion to be uncorrelated with narcissism, unlike self-esteem, and to show a stable contribution to psychological well-being. **Key References** - Baumeister, Campbell, Krueger, & Vohs (2003) *Psychol Sci Public Interest* 4(1) - Bandura (1997) *Self-Efficacy: The Exercise of Control* - Neff (2003) *Self and Identity* 2(2,3) - Bushman & Baumeister (1998) *J Pers Soc Psychol* 75(1) - Crocker & Park (2004) *Psychological Bulletin* 130(3)

## Critical Reassessment of the Self-Esteem Construct **The Turning Point: Baumeister 2003** Baumeister et al. (2003, *Psychological Science in the Public Interest*) rejected through large-scale meta-analysis the traditional claim that high self-esteem improves academic, occupational, and interpersonal outcomes. They identified the absence of causal evidence, self-report bias, and the problem of "inflated self-esteem," raising fundamental questions about the American self-esteem movement of the 1970s–90s. **Contrast with Self-Efficacy (Bandura)** Bandura's self-efficacy — "beliefs about one's capacity to perform a specific task" — is domain-specific and has high behavioral predictive validity. After the Baumeister critique, researchers increasingly came to regard self-efficacy as having greater practical predictive validity than global self-esteem. **The Rise of Self-Compassion (Neff)** Neff's (from 2003) self-compassion — comprising three elements (self-kindness, common humanity, mindfulness) — attracted attention as a construct that provides psychological stability independent of the level of self-evaluation. It has gained stronger empirical support than self-esteem for avoiding self-criticism and coping with failure, and integration into clinical contexts (CBT, ACT) is advancing. --- **Key References** - Baumeister, R. F., et al. (2003). Does high self-esteem cause better performance? *Psychological Science in the Public Interest, 4*(1), 1–44. - Neff, K. D. (2003). Self-compassion: An alternative conceptualization of a healthy attitude toward oneself. *Self and Identity, 2*(2), 85–101. - Bandura, A. (1997). *Self-efficacy: The exercise of control*. Freeman. - Twenge, J. M., & Crocker, J. (2002). Race and self-esteem. *Psychological Bulletin, 128*(3), 371–408. - Zeigler-Hill, V. (2011). The connections between self-esteem and psychopathology. *Journal of Contemporary Psychotherapy, 41*(3), 157–164.

Theory on the structure of self-criticism shifted through the twentieth century from "the internalized punisher" to "thought as a modifiable object." **Freud (1923)** proposed the **superego (Über-Ich)** in *The Ego and the Id*. Formed by internalizing parental prohibitions during the Oedipal period, it monitors and punishes the ego, generating guilt — the developmental, unconscious origin of self-criticism. **Karen Horney (1950)**, in *Neurosis and Human Growth*, moved away from Freudian drive theory toward interpersonal relations. She described the **"tyranny of the shoulds"** — imperatives imposed by an idealized self-image — as an internal compulsion that produces self-alienation. **Albert Ellis (around 1955)** founded Rational Emotive Behavior Therapy (REBT), using the ABC model to argue that **irrational beliefs** — especially "must/should" thinking (musturbation) — cause emotional disturbance. This lineage operationalized Horney's "shoulds" cognitively and empirically. **Aaron Beck (1960s)** established cognitive therapy, systematizing **cognitive distortions** — all-or-nothing thinking, overgeneralization, personalization — and negative automatic thoughts. He identified the cognitive triad of depression, enabling structured intervention. **Brené Brown (2000s–)**, through qualitative research, distinguished **shame** from guilt. "I am bad" is shame; "I did bad" is guilt. She proposed vulnerability and self-compassion as the path to recovery. The trajectory unfolds: unconscious tribunal (Freud) → interpersonal compulsion (Horney) → thought as cognitive target (Ellis, Beck) → relational emotion destigmatized (Brown). **Key References** - Freud, S. (1923). *Das Ich und das Es*. - Horney, K. (1950). *Neurosis and Human Growth*. - Ellis, A. (1962). *Reason and Emotion in Psychotherapy*. - Beck, A. T. (1979). *Cognitive Therapy of Depression*. - Brown, B. (2012). *Daring Greatly*.

## The Structure of Self-Criticism: A Lineage **Freud (1923)**: The superego concept as the starting point. Formalized self-punishment and moral sanction functions as the internalization of parental and social norms. **Horney (1950, *Neurosis and Human Growth*)**: Proposed the "tyranny of the should." Argued that the gap between the idealized and real self generates chronic self-loathing. **Ellis (1955, founder of REBT)**: Systematized as "irrational beliefs." Positioned absolute demands such as "I must be perfect" as the cognitive basis of self-blame. **Beck (1960s, cognitive therapy)**: Showed that "cognitive distortions" — all-or-nothing thinking, overgeneralization, mental filter — structure self-critical automatic thoughts. His influence on DSM diagnostic criteria was also significant. **Brown (2010s, shame research)**: Empirically distinguished "shame (= sense of being defective as a person)" from "guilt (= regret over an action)." Argued that shame is the core of chronic self-criticism and social avoidance. --- ### Key References - Freud, S. (1923). *The Ego and the Id*. SE Vol. 19. - Horney, K. (1950). *Neurosis and Human Growth*. Norton. - Ellis, A. (1962). *Reason and Emotion in Psychotherapy*. Lyle Stuart. - Beck, A. T. (1979). *Cognitive Therapy of Depression*. Guilford Press. - Brown, B. (2010). "The Gifts of Imperfection." *Hazelden Publishing.*

## Influence of the Buddhist Middle Way, Emptiness, and Dependent Origination on MBSR and ACT **Origins and the Bridging Figure** Mindfulness meditation derives from Theravada vipassana and Zen. When Jon Kabat-Zinn founded MBSR at the University of Massachusetts Medical Center in 1979, he transplanted it into clinical settings by stripping Buddhist context — he reconceived the spirit of the middle way as "a balance between effort and acceptance." **The Mechanism of Emptiness and Dependent Origination** Nāgārjuna's *Mūlamadhyamakakārikā* (c. 2nd century CE) teaches emptiness (the negation of *svabhāva*) and dependent origination — viewing phenomena not as fixed entities but as relational flows. This became the theoretical basis for decentering: "thoughts are not facts but transient events." **Influence on ACT** ACT, established by Steven Hayes et al. in the 1980s, is grounded in functional contextualism and Relational Frame Theory (RFT), while emphasizing defusion from cognitive fusion and a perspective of self-as-context. This structurally corresponds to the anātman (no-self) and emptiness view. The middle way appears as an accepting posture avoiding both poles of "experiential avoidance" and "excessive identification." Both therapies secularize and inherit the four noble truths in their aim not to eliminate suffering but to transform one's relationship to it. --- **Key References** - Kabat-Zinn, J. (1990) *Full Catastrophe Living* - Hayes, S. C., Strosahl, K., Wilson, K. (1999/2012) *Acceptance and Commitment Therapy* - Garfield, J. L. (1995) *The Fundamental Wisdom of the Middle Way* (English translation and commentary on the *Mūlamadhyamakakārikā*) - Gethin, R. (2011) "On some definitions of mindfulness," *Contemporary Buddhism* - Williams, J. M. G. & Kabat-Zinn, J. (2011) "Mindfulness: diverse perspectives on its meaning, origins, and applications," *Contemporary Buddhism* (approx. 580 characters)

## Buddhist Philosophy and Its Influence on MBSR and ACT **The Logical Core of the Middle Way and Emptiness** Nāgārjuna (c. 2nd–3rd century CE) logically elaborated "emptiness" (śūnyatā) — the negation of fixed entities — and "dependent origination" in the *Mūlamadhyamakakārikā*. The view that neither self nor phenomena are fixed entities but arise within relationship philosophically refined the original Buddhist middle way's conception of suffering as "attachment to the self." **The Path to MBSR** When Jon Kabat-Zinn developed MBSR in 1979, he secularized and medicalized Zen and Theravada meditation practices. "Non-judgmental observation" structurally corresponds to the emptiness epistemology of not attaching substantive labels to phenomena. **The Path to ACT** Steven Hayes's ACT (from 1986) places "defusion" from thoughts at its core. "Self-as-context" — viewing the self as a contextual observer — is functionally isomorphic with a dependent-origination, no-self view of the self; Hayes himself has explicitly acknowledged the affinity with Buddhism. --- **Key References** - Kabat-Zinn, J. (1990). *Full Catastrophe Living*. Delacorte Press. - Hayes, S.C., Strosahl, K., & Wilson, K.G. (1999). *Acceptance and Commitment Therapy*. Guilford. - Williams, J.M.G., & Kabat-Zinn, J. (2011). Mindfulness: Diverse perspectives. *Contemporary Buddhism*, 12(1). - Garfield, J.L. (1995). *The Fundamental Wisdom of the Middle Way* (Nāgārjuna's Mūlamadhyamakakārikā). Oxford UP. - Analayo, B. (2003). *Satipaṭṭhāna: The Direct Path to Realization*. Windhorse.

Among the core concepts of Adler's Individual Psychology, "separation of tasks" (Aufgabe der Trennung / separation of tasks) is the idea of distinguishing one's own tasks from those of others on the basis of who ultimately bears the consequences of a matter. Others' evaluations and expectations are their tasks; one does not intrude on them. "Community feeling" (Gemeinschaftsgefühl / social interest) refers to the sense of belonging and contribution — seeing others as companions and feeling oneself part of a community. The two are not in opposition: after separating tasks to organize interpersonal relationships, one moves toward community feeling as the ultimate goal. It should be noted academically that the formulation "separation of tasks" is colored more by Ichiro Kishimi's organizing and naming than by Adler's own terminology. Alfred Adler (1870–1937) was one of the early psychoanalysts alongside Freud and Jung, but his profile in Japan was long low. The turning point was *The Courage to Be Disliked* by Ichiro Kishimi and Fumitake Koga (Diamond Publishing, 2013), which presented "denial of the need for approval," "teleology," and "separation of tasks" accessibly in a dialogue format between a philosopher and a young man, becoming a bestseller. The sequel *The Courage to Be Happy* (2015) and a Fuji TV drama adaptation in 2017 established an "Adler book" boom in the self-help context. On the other hand, there are criticisms of popularization that strips away the asceticism and clinical system of the original texts, and specialists have encouraged reference to the original works (e.g., *Lectures on Individual Psychology*). Key References - Kishimi Ichiro & Koga Fumitake, *The Courage to Be Disliked* (Kirawareru Yuki), Diamond Publishing, 2013 - Kishimi Ichiro & Koga Fumitake, *The Courage to Be Happy*, Diamond Publishing, 2015 - A. Adler, *What Life Should Mean to You*, 1931 - Kishimi Ichiro, *Introduction to Adlerian Psychology* (Best Shinsho, 1999) - H. L. Ansbacher & R. R. Ansbacher (eds.), *The Individual Psychology of Alfred Adler*, 1956

## Reassessment of Adlerian Individual Psychology Alfred Adler (1870–1937) proposed **separation of tasks** (Aufgabentrennung): "not intervening in others' tasks and concentrating on one's own" — a boundary concept. **Community feeling** (Gemeinschaftsgefühl) is the health indicator at the core: the sense of belonging to and will to contribute to others, society, and the universe, contrasted with Freud's drive theory. *The Courage to Be Disliked* (Kishimi Ichiro & Koga Fumitake, 2013, Diamond Publishing) presented this accessibly in philosophical dialogue form, becoming a bestseller with over 3.3 million copies (domestic Japan). Resonating with the "approval-fatigue" of the social media era, separation of tasks spread rapidly as practical wisdom for "cutting off concern for others' evaluations" in workplace, child-rearing, and mental health contexts. In academic circles, criticism also arose regarding contextual coherence within Adlerian frameworks (concern about misappropriation as self-responsibility discourse), but since 2015 the Japan Adlerian Psychology Association has successively published explanatory materials emphasizing its inseparability from community feeling. --- **Key References** - Adler, A. (1927). *Menschenkenntnis*. Hirzel. - Ansbacher, H. L., & Ansbacher, R. R. (Eds.). (1956). *The Individual Psychology of Alfred Adler*. Basic Books. - Kishimi Ichiro & Koga Fumitake (2013). *The Courage to Be Disliked* (*Kirawareru Yuki*). Diamond Publishing. - Japan Adlerian Psychology Association (2016). "Fundamental Concepts and Applications of Adlerian Psychology." *Adlerian Psychology Research* 10(1). - Watts, R. E. (2012). Adlerian counseling. In D. Capuzzi & D. R. Gross (Eds.), *Counseling and Psychotherapy* (5th ed.). American Counseling Association.

The **1937 Elixir Sulfanilamide disaster** occurred when the US company S.E. Massengill dissolved the antibiotic sulfanilamide in **diethylene glycol** (a component of automotive antifreeze) to produce a syrup formulation and placed it on the market without conducting any toxicity testing. Because the existing 1906 Pure Food and Drugs Act could only regulate adulterants and false labeling, there was no legal basis to require proof of safety before marketing. Approximately 100 people — many of them children — died of renal failure. Chemist Harold Watkins subsequently took his own life. This tragedy was the direct impetus for Congress to enact the **Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938**. Under this law, manufacturers became obligated to submit safety data to the FDA before marketing (NDA, New Drug Application), and the FDA was empowered to review them — establishing the modern pre-approval review system. In current mainstream understanding, this incident is identified as the origin of the **"premarket approval"** regulatory paradigm. However, the 1938 law did not include efficacy review; that supplement had to await the 1962 Kefauver-Harris Amendments (prompted by the thalidomide disaster). The lesson is the shift from reactive post-harm regulation to proactive regulation that prevents untested products from entering the market in the first place. **Key References** - Wax, P.M. (1995). "Elixir, Diluents, and the Passage of the 1938 FD&C Act." *Annals of Internal Medicine*, 122(6). - FDA. "Sulfanilamide Disaster" (FDA History, *FDA Consumer* 1981, C. Ballentine). - Carpenter, D. (2010). *Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA*. Princeton Univ. Press. - Hilts, P.J. (2003). *Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation*. - Federal Food, Drug, and Cosmetic Act of 1938 (Pub.L. 75–717). (approx. 650 characters)

## 1937 Elixir Sulfanilamide Disaster: Regulatory and Institutional Lessons S.E. Massengill Company used diethylene glycol (DEG) to dissolve sulfanilamide and marketed the resulting elixir, killing 107 people in the United States. The 1906 Pure Food and Drugs Act **had no obligation for pre-market safety review**, and the only basis for recall was the technical violation of the "elixir" label (since it contained no alcohol). This disaster was the direct catalyst for enactment of the **Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938**. Key lessons and institutional outcomes: - **Mandatory pre-market proof of safety**: Manufacturers must submit safety data to the FDA; sales without approval are prohibited - **Establishment of government pre-approval authority**: The "burden of proving harmlessness" was shifted to companies - **Necessity of toxicity evaluation of excipients and solvents**: Not only the active ingredient but the entire formulation became subject to regulation - **Origins of GFI (Good Faith Investigation) systems**: A paradigm shift from post-hoc recall to pre-emptive regulation --- **Key References** - Ballentine, C. (1981). "Taste of raspberries, taste of death." *FDA Consumer*, 15(5). - Wax, P.M. (1995). "Elixirs, diluents, and the passage of the 1938 Federal Food, Drug, and Cosmetic Act." *Annals of Internal Medicine*, 122(6), 456–461. - Carpenter, D. (2010). *Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA*. Princeton University Press. - Young, J.H. (1989). *Pure Food: Securing the Federal Food and Drugs Act of 1906*. Princeton University Press.

## The Thalidomide Disaster (1957–1962) — Regulatory Lessons and the Role of Frances Kelsey **Background** In 1957, the West German company Grünenthal launched thalidomide (brand name Contergan) as a sedative and hypnotic, and it was widely used by pregnant women for morning sickness. Between 1959 and 1962, an estimated 10,000 infants worldwide were born with severe congenital abnormalities involving limb truncation — **phocomelia**. In 1961, German pediatrician Widukind Lenz and Australian obstetrician William McBride independently identified the association between the drug and its teratogenicity, leading to its withdrawal. **Regulatory and Institutional Lessons** The disaster exposed the danger of marketing without pre-approval of efficacy and safety, and transformed pharmaceutical regulation worldwide. In the United States, the **Kefauver-Harris Amendments of 1962** were enacted, introducing (1) mandatory pre-approval proof of efficacy, (2) proper manufacturing standards and rigorous clinical trials (including informed consent), and (3) an adverse event reporting system. The UK established the Dunlop Committee in 1963, followed by the Medicines Act 1968 and the Yellow Card system. Standardization of teratogenicity testing also advanced. **The Role of Frances Kelsey** FDA reviewer Kelsey was assigned in 1960 to handle the Richardson-Merrell application for thalidomide (Kevadon) in the US. She repeatedly withheld approval, citing reports of peripheral neuropathy and deficiencies in safety data, preventing large-scale entry of the drug into the US market. In 1962, she received the Federal Distinguished Civilian Service Award from President Kennedy, and became a symbolic figure behind the Kefauver-Harris Amendments. The FDA subsequently established the "Kelsey Award" in her honor. **Key References** - Kelsey, F.O. "Thalidomide Update: Regulatory Aspects." *Teratology* (1988) - McBride, W.G. "Thalidomide and Congenital Abnormalities." *The Lancet* (1961) - Lenz, W. "A Short History of Thalidomide Embryopathy." *Teratology* (1988) - U.S. FDA, *Kefauver–Harris Amendments of 1962* (institutional history) - Stephens, T. & Brynner, R. *Dark Remedy: The Impact of Thalidomide* (2001)

## The Thalidomide Disaster and Regulatory Lessons **Background**: In 1957, Grünenthal (West Germany) launched it as a sedative and morning-sickness drug. Approved in over 46 countries, by 1961 approximately 10,000 infants with limb deformities had been reported. Widukind Lenz (Germany) and William McBride (Australia) independently reported teratogenicity; the drug was withdrawn from the market the same year. **Kelsey's Role**: FDA reviewer Frances Oldham Kelsey rejected the Richardson-Merrell US application six times in 1960, citing insufficient peripheral neuritis data and inconsistencies in animal studies. This judgment limited damage in the United States. In 1962 she received the Presidential Medal for Distinguished Federal Civilian Service from President Kennedy. **Institutional Lessons**: - The 1962 Kefauver-Harris Amendments strengthened FDA authority — mandatory pre-approval proof of efficacy and regulation of clinical trials were codified in law - Establishment of ethical standards for trials involving vulnerable populations including pregnant women - Mandatory teratogenicity testing (developmental toxicity studies) - Development of post-market safety surveillance (pharmacovigilance) systems --- **Key References** - Kelsey FO. *Thalidomide update: regulatory aspects.* Teratology. 1988;38(3):221-226. - Bren L. *Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History.* FDA Consumer. 2001. - Vargesson N. *Thalidomide-induced teratogenesis: history and mechanisms.* Birth Defects Res C. 2015;105(2):140-156. - Kim JH, Scialli AR. *Thalidomide: the tragedy of birth defects and the effective treatment of disease.* Toxicol Sci. 2011;122(1):1-6. - Stephens T, Brynner R. *Dark Remedy: The Impact of Thalidomide.* Basic Books; 2001.

The SMON disaster was the decisive turning point that shifted Japan's pharmaceutical safety regulation toward active surveillance. **Background and Impact** From the late 1950s, subacute myelo-optico-neuropathy (SMON) occurred frequently among users of the antidiarrheal agent clioquinol, affecting over 10,000 people. In 1970, Tadao Tsubaki et al. at Niigata University epidemiologically identified clioquinol as the cause; when the Ministry of Health that year ordered sales to be suspended, new cases virtually disappeared, confirming the causal link. Litigation from 1971 onward was settled in 1979. Directly motivated by this damage, the Pharmaceutical Affairs Act underwent a major revision in 1979. In addition to legalizing efficacy and safety review at the time of approval, the **post-marketing re-examination system** and **re-evaluation system** were introduced, establishing a framework for continuous benefit-risk verification even after marketing. That same year, the Drug Side Effects Injury Relief System (now PMDA relief benefits) was also created. This is identified as the institutional starting point for Japan's PMS (post-marketing surveillance, now GVP/GPSP and Risk Management Plans), inherited in the current Act on Pharmaceutical and Medical Devices (PMDA). SMON is positioned as the emblematic case that established domestically the modern pharmacovigilance ethos that "approval is not the endpoint of safety, but surveillance across the entire lifecycle is necessary." **Key References** - Tadao Tsubaki, "Epidemiology of SMON" (1971, core of causal identification in Japan) - MHLW Pharmaceutical Affairs Bureau, *Commentary on the Pharmaceutical Affairs Act Amendment* (1979 revision, re-examination and re-evaluation systems) - Fukuda Makoto et al., "Drug-Induced SMON and Pharmaceutical Administration," *Pharmaceutical and Medical Device Regulatory Science* - PMDA, *History of the Drug Side Effects Injury Relief System* - WHO, "The Importance of Pharmacovigilance" (2002, international PMS framework) (strictly approximately 650 characters; dates, names, and system names were preserved as a priority)

## The SMON Disaster and Its Impact on PMS Systems **Case Summary**: Between approximately 1955 and the 1970s, around 11,000 people developed SMON from the antidiarrheal drug clioquinol (Vioform). Tamura Yoshihito et al. identified the cause in 1970; sales were prohibited the same year. **Institutional Turning Points**: 1. **1979 Pharmaceutical Affairs Act Revision**: Post-approval safety re-evaluation systems were codified. Manufacturers were required to report adverse reactions (the prototype of the re-evaluation and re-examination systems). 2. **Drug Side Effects Injury Relief System (1980)**: The Act on Drug Side Effects Injury Relief Fund created an administrative compensation system that, uniquely in the world, required no proof of negligence. 3. **Mandatory PMS**: Company-led use-results surveys and specified use-results surveys were institutionalized, making systematic post-approval data collection mandatory (predecessor to the current GVP Ministerial Ordinance). 4. **International Reach**: In the ICH E2 series discussions (Periodic Safety Update Reports: PSURs), Japan's experience became a rationale for the need to fill "institutional gaps in post-approval surveillance." --- **Key References** - Tsubaki Tadao et al., "Clinical Features and Epidemiology of SMON," *Neurology*, 1971 - MHLW, "Research Group Report on SMON," 1972 - Pharmaceutical Affairs Act (1979 revision, Act No. 56) Statement of Reasons, 1979 - Act on Drug Side Effects Injury Relief Fund (1980, Act No. 76) - Yoshitake T. et al., "SMON and clioquinol: epidemiological and experimental findings," *Jpn J Med Sci Biol*, 1975

The HIV-contaminated blood products disaster (1980s, in which HIV infection spread among hemophiliac patients administered non-heat-treated blood coagulation factor preparations — approximately 1,400 infected) is regarded as a textbook case of "organized irresponsibility" implicating all three parties: administration, specialists, and industry. **Core Structural Failures (Mainstream Understanding)** - **Minimization of foreseeability**: By around 1983, heat-treated preparations had been approved in the United States and the danger was internationally shared, yet the Ministry of Health and Welfare (then) and the research group (led by Abe Takeshi et al.) delayed recall and transition away from non-heat-treated preparations. Market protection and protection of domestic manufacturers were prioritized, in the prevailing assessment. - **Regulatory capture**: The AIDS research group had conflicts of interest entangling them with pharmaceutical companies, and the administration delegated judgment entirely to the expert group, causing independent safety evaluation to fail to function. - **Absence of the precautionary principle**: Uncertainty was used as an excuse for inaction under the rubric of "insufficient evidence." Modern medical ethics holds that when harm is serious and irreversible, preventive measures should be taken without waiting for confirmation. - **Diffusion of accountability**: A structure in which no one was the final decision-maker made pursuit of responsibility difficult. Following the 1996 settlement and discovery of the Gunji Files, institutional preservation of administrative records and transparency of decision-making became systemic imperatives. **Lessons for the Present**: These led to establishment of the Pharmaceuticals and Medical Devices Agency (PMDA) (2004), conflict-of-interest management, strengthened pharmacovigilance, patient-participatory decision-making, and the establishment of an administrative accountability doctrine that "inaction is also a decision." **Key References** - MHLW, *Report on Investigation of HIV Infection from Blood Products (Gunji Files related)*, 1996 - Yamada Kaneo et al., "Review of the AIDS-Contaminated Blood Products Problem," Journal of the Japan AIDS Society - Muto Kaori, *AIDS-Contaminated Blood Products and Bioethics*, medical ethics-related collected essays - Kurihara Chieko, "The Precautionary Principle and Drug Disasters," Science and Technology Studies Research - Katahira Kiyohiko, *No More Drug Disasters* (expanded ed.), Kiri-shobo, 2006

## Structural Failures of the HIV-Contaminated Blood Products Disaster and Modern Lessons **Factual Skeleton**: In the 1980s, an "iron triangle" centered on Professor Abe Takeshi at Teikyo University, specialists in blood products, the Ministry of Health and Welfare Pharmaceutical Affairs Bureau, and Green Cross continued distribution of non-heat-treated concentrated blood coagulation factor preparations. Even after the US FDA approved heat-treated preparations in 1983, Japan's approval was delayed until 1985. HIV infections reached approximately 1,800 people, centered on hemophilia patients. **Three Layers of Structural Failure** 1. **Institutional neglect of conflicts of interest**: Pharmaceutical Advisory Committee members received research funding from pharmaceutical companies while participating in approval review. No mechanism for independence review existed. 2. **Information closure and bureaucratic self-protection**: As revealed by the discovery of "undisclosed documents" by Health Minister Naoto Kan in 1996, risk information was sealed internally, and the concept of a disclosure obligation to patients was absent. 3. **Irresponsibility structure through diffusion of responsibility**: A multi-layered structure in which administration, companies, and physicians could each claim "I followed others' judgment" suppressed individual ethical judgment (Responsibility Diffusion). **Reflection in Modern Medical Ethics and Administrative Accountability Theory**: This case exposed the limits of the Drug Side Effects Injury Relief Act (1979), and led to revision of the drug adverse event relief system, the Pharmaceutical Affairs Act revision (2002), and mandatory conflict-of-interest management guidelines. In ethical analysis, it is analyzed as "organizational evil" (applied from Hannah Arendt's banality of evil). --- **Key References** - Hashimoto Kimihiro, *The Truth of the HIV-Contaminated Blood Products Case* (2000, Iwanami Shoten) - Feldman, E. & Bayer, R. (eds.) *Blood Feuds: AIDS, Blood, and the Politics of Medical Disaster* (1999, Oxford UP) - MHLW "AIDS Research Group" materials (1983–85), documents published by Minister Naoto Kan (1996) - Yoshida Katsumi, "Drug Disaster Litigation and State Compensation Liability," *Horita Journal* Vol. 68 No. 10 (1996) - Kato Hisatake, *Introduction to Contemporary Ethics* (1997, Kodansha) Chapter 8, "Medicine and Responsibility"

A summary of the state's (Ministry of Health and Welfare / Ministry of Health, Labour and Welfare) information management responsibility in the fibrinogen-hepatitis C disaster, from the perspective of mainstream medical policy history. --- **Structure of State Information Management Responsibility** Fibrinogen preparations (manufactured by the former Green Cross) were approved in 1964, but pre-heat-treatment preparations carried a high risk of hepatitis C virus contamination, and by 1977 the FDA in the United States was moving toward withdrawal of approval. Japan's response was delayed, and non-heat-treated preparations were used through the late 1980s. In the mainstream understanding, state responsibility is captured in three layers. First, **failure to exercise regulatory authority** — the state possessed approval and re-evaluation authority under the Pharmaceutical Affairs Act yet overlooked continued manufacturing and sales despite awareness of the danger (inaction partially recognized in fibrinogen-hepatitis C litigation from 2002 onward, including the Osaka District Court ruling of 2006). Second, **non-disclosure and neglect of information** — the Ministry of Health, Labour and Welfare identified a list of preparation recipients (418 cases, etc.) by 2002 yet did not notify the patients themselves; in 2007, the fact that "the existence of the materials had not been disclosed publicly" came to light and became a political issue. This is regarded as the core of information management responsibility. Third, **absence of individual relief**. In 2008, the **Special Measures Act for Relief of Hepatitis C Victims** was enacted by member's bill under the Fukuda Yasuo Cabinet, and relief shifted to a uniform basis. Following the **final recommendation** that same year, from 2009 the MHLW advanced "review of pharmaceutical administration for prevention of recurrence of drug disasters," recommending establishment of a third-party oversight body. The understanding that early collection, personal notification, and public disclosure of information are affirmative state obligations has become established. --- **Key References** - Review Committee for Investigation of the Fibrinogen-Related Hepatitis C Disaster and Prevention of Recurrence — "Final Recommendation" (2010) - MHLW, *List of Medical Institutions Supplied with Fibrinogen Preparations* — related published materials (2007) - Special Measures Act for Hepatitis C (2008, member's bill) - Tatara Kozo et al., essays related to public health and medical policy history - National Association of Attorneys in the Fibrinogen-Hepatitis C Litigation, *History of the Fibrinogen-Hepatitis C Trial*

## State Information Management Responsibility in Japan's Fibrinogen-Hepatitis C Disaster In the 1970s–80s, the Ministry of Health and Welfare (now MHLW) was aware of the hepatitis C virus infection risk from fibrinogen preparations yet delayed product recall and withdrawal. After the FDA (US) prohibited the preparations in 1987, Japan continued approval until 1994. The decisive problem is **non-disclosure and systematic concealment**. Although the MHLW compiled a list of preparation recipients in the 1990s, it did not notify the victims until 2002. The 2007 Osaka High Court ruling (fibrinogen-hepatitis C litigation) and Diet deliberations recognized "administrative inaction." Enactment of the "Special Measures Act Concerning Relief and Support for Hepatitis C Victims" in 2008 and the apology by Prime Minister Fukuda Yasuo are positioned in medical policy history as the outcome of a structural failure in which the regulatory authority prioritized corporate interests and departmental self-interest, and neglected the obligation to disclose risk information to patients. --- **Key References** - Wada Koji et al., "Hepatitis C Litigation and Administrative Responsibility," *Medicine and Society*, 2009 - MHLW, *Final Recommendation of the Review Committee for the Fibrinogen-Related Hepatitis C Disaster and the Reform of Pharmaceutical Administration for Prevention of Recurrence*, 2010 - Leflar, R.B. "Public Accountability and Medical Dispute Resolution in Japan." *Law & Contemporary Problems*, 2009 - Idegawa Masahiko, *Why Do Drug Disasters Never End?* Iwanami Shoten, 2013 - Miyajima Mitsuji, "The Structure of Drug Disaster Ethics," *Bioethics*, 2011